William Blair & Company
PVLA

William Blair & Company’s Palvella Therapeutics PVLA Stock Holding History

William Blair & Company’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-232
Closed -$18.1K – 1878
2023
Q1 		$18.1K Hold
232
– – ﹤0.01% 1689
2022
Q4 		$19.3K Sell
232
-500
-68% -$40.2K ﹤0.01% 1687
2022
Q3 		$67K Sell
732
-907
-55% -$117K ﹤0.01% 1556
2022
Q2 		$245K Buy
1,639
+30
+2% +$5.47K ﹤0.01% 1343
2022
Q1 		$390K Buy
1,609
+134
+9% +$35.2K ﹤0.01% 1259
2021
Q4 		$446K Buy
1,475
+1,287
+685% +$412K ﹤0.01% 1260
2021
Q3 		$78K Hold
188
– – ﹤0.01% 1644
2021
Q2 		$57K Sell
188
-562
-75% -$123K ﹤0.01% 1678
2021
Q1 		$154K Buy
750
+125
+20% +$27.3K ﹤0.01% 1529
2020
Q4 		$125K Buy
+625
New +$130K ﹤0.01% 1521
2018
Q2 		– Sell
-138
Closed -$75K – 1642
2018
Q1 		$75K Buy
+138
New +$85.4K ﹤0.01% 1302

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

William Blair & Company's PVLA Position: Q2 2023 in Review

William Blair & Company sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 232 shares — an estimated $18.1K sold.

William Blair & Company first reported a position in PVLA in Q1 2018 and held it in 11 quarters. The position peaked at $446K in Q4 2021. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • William Blair & Company reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • William Blair & Company sold 232 Palvella Therapeutics shares in Q2 2023, an estimated $18.1K.
  • William Blair & Company first reported a position in Palvella Therapeutics in Q1 2018 and held it in 11 quarters.
  • William Blair & Company's Palvella Therapeutics position peaked at $446K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on William Blair & Company's 13F filing for Q2 2023, filed 11 Aug 2023.